JMP Securities analyst Jonathan Wolleben maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Market Outperform and raises the price target from $381 to $385.
JMP Securities Maintains Market Outperform on Madrigal Pharmaceuticals, Raises Price Target to $385
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.